Skip to main content

Table 2 Mutational status in plasma and tissue

From: Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients

Mutational status

No. (%)

Plasma (N = 126)

Tissue (N = 126)

Wild-type

69 (54.8)

74 (58.7)

KRAS mutation

35 (27.8)

41 (32.5)

NRAS mutation

1 (0.8)

3 (2.4)

BRAF mutation

4 (3.2)

3 (2.4)

PIK3CA mutation

4 (3.2)

4 (3.2)

KRAS + PIK3CA mutations

12 (9.5)

1 (0.9)

NRAS + PIK3CA mutations

1 (0.8)

0 (0)